https://www.appliedxl.com/news/precision-io-epione-2026-data-nct07325578 Biopharma News en 2026-07-20T13:15:19.206Z Precision IO presents Epione robotic MSK ablation data at SRS meeting https://www.appliedxl.com/news/prolocor-pfcg-test-2026-readout-nct05175261 Biopharma News en 2026-07-20T13:34:49.542Z Prolocor biomarker links high pFCG to repeat heart attacks in 765-patient study https://www.appliedxl.com/news/actinogen-xanamem-emestedastat-readout-nct05657691-0c7b84 Biopharma News en 2026-07-20T13:25:25.840Z Xanamem misses cognition goal in depression trial, eases mood symptoms https://www.appliedxl.com/news/kolon-tissuegene-tg-c-2026-readout-nct03291470 Biopharma News en 2026-07-20T12:14:56.969Z Kolon TissueGene's TG-C fails first Phase 3 knee osteoarthritis trial https://www.appliedxl.com/news/treeline-tln-121-2026-readout-nct07082803 Biopharma News en 2026-07-20T11:45:05.164Z Treeline's BCL6 degrader TLN-121 posts 84% response rate in lymphoma https://www.appliedxl.com/news/nouscom-nous-209-2026-readout-nct05078866 Biopharma News en 2026-07-20T11:15:07.080Z Nouscom's NOUS-209 shows durable T-cell response, no new polyps at 1 year https://www.appliedxl.com/news/corestemchemon-neuronata-r-lenzumestrocel-2026-readout-nct04745299 Biopharma News en 2026-07-19T23:15:14.186Z CorestemChemon's ALS stem cell therapy missed its Phase 3 primary in the full population https://www.appliedxl.com/news/hrs-7535-diabetic-kidney-disease-readout-nct06415214 Biopharma News en 2026-07-19T19:15:24.510Z HRS-7535 cut albuminuria 32% versus placebo in diabetic kidney disease trial https://www.appliedxl.com/news/sglt2-inhibitors-post-mi-meta-analysis Biopharma News en 2026-07-19T19:24:45.213Z SGLT2 inhibitors cut heart failure hospitalization after MI without diabetes https://www.appliedxl.com/news/tegoprazan-h-pylori-non-inferiority Biopharma News en 2026-07-19T19:44:50.146Z Tegoprazan dual therapy misses non-inferiority mark against bismuth quadruple therapy for H. pylori https://www.appliedxl.com/news/regenxbio-surabgene-lomparvovec-sura-vec-abbv-rgx-314-nct03066258 Biopharma News en 2026-07-19T09:05:49.913Z REGENXBIO's sura-vec holds vision gains through 5 years in a 42-patient wet AMD cohort https://www.appliedxl.com/news/romosozumab-osteogenesis-imperfecta-data Biopharma News en 2026-07-19T19:54:50.029Z Romosozumab lifts spinal bone density in osteogenesis imperfecta but not the hip https://www.appliedxl.com/news/perfusion-guided-fluid-resuscitation-acute-skin-failure Biopharma News en 2026-07-18T19:14:50.054Z Perfusion-guided fluid strategy cuts skin failure in elderly ICU patients https://www.appliedxl.com/news/novo-nordisk-denecimig-hemophilia-frontier4-nct05685238 Biopharma News en 2026-07-18T19:35:12.265Z Denecimig every-2-weeks dosing holds up in 26-week FRONTIER4 hemophilia A interim look https://www.appliedxl.com/news/ropeginterferon-polycythemia-vera-dosing Biopharma News en 2026-07-18T20:24:47.031Z Ropeginterferon analysis links faster dosing to quicker phlebotomy-free control in PV